Vanessa Carle PhD
Principal
Gate Bioscience is developing Molecular Gates, a new frontier in protein elimination.
Founded in 2021, Gate Bioscience is creating a new class of small molecule therapeutics: Molecular Gates. Molecular Gates are small molecule drugs that selectively eliminate harmful extracellular proteins at their origin, inside cells, and prevent them from emerging to cause disease. There are more than 4,000 extracellular proteins, over 1,000 of which are linked to a disease. By eliminating the disease-causing protein, they aim to eliminate the disease.
The company's science is fueled by their Molecular Gate Discovery Platform™, which combines their privileged library of Molecular Gates, suite of bespoke secretion-focused assays and technologies, and deep expertise into the biology of the secretory pathway. The platform enables precise, rapid, and repeatable drug discovery. And it gets stronger with every Molecular Gate program.
Gate Biosciences is led and advised by a team of world-class drug developers and entrepreneurs, and is backed by leading venture investors.
Industry
Biotech
Year Invested
2025
Status
Current
Location
USA
Molecular gates have the potential to be transformative drugs for diseases where current treatments fall short. Because the mechanism is so differentiated, we’ve been able to build a portfolio with low biology risk and best-in-class potential across multiple therapeutic areas.Jordi Mata-Fink, Ph.D.
Co-Founder & CEO
